Product Description
ARC-02 selectively binds CD79b-positive B-cells and delivers monomethyl auristatin E (MMAE), a clinically validated anti-cancer payload, directly to tumor cells. It is the first clinical candidate generated using Araris’ proprietary AraLinQ® ADC technology and Arastatin™ linker-payload, designed for precise intracellular release and minimization of impact on healthy tissue. (Sourced from: https://www.taihooncology.com/us/news/araris-biotech-ag-and-taiho-oncology-announce-dosing-of-first-patient-in-phase-1-trial-of-arc-02-a-novel-adc-for-the-treatment-of-non-hodgkin-lymphoma/)
Mechanisms of Action: CD79 Antagonist
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Otsuka
Company Location:
Company Founding Year: 1921
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, France, Italy, Poland, Spain, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07691606 |
ABLATE-101 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma |
2029-01-01 |
12% |
2026-07-10 |
Recent News Events
Date |
Type |
Title |
|---|